ATNX

Athenex Inc

$3.69

+0.03 (+0.82%)

chg neg

quotes and stock data may be delayed 15 minutes

52 wk low

3.52

52 wk hi

15.24

Cash

$187.7M

Burn Rate (Qtr)

$23.1M

Mkt Cap

$345.1m

Avg Volume

1,286,507

*cash/burn updated:

Q1 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Oral paclitaxel + encequidar

Metastatic breast cancer, Cancer, Solid tumor/s

Phase 3

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Oral Paclitaxel + encequidar w/ dostarlimab

Cancer, Breast cancer

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Oral Paclitaxel +encequidar

Angiosarcoma, Cancer

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Oral paclitaxel + encequidar w/ ramucirumab

Gastric cancer, Cancer

Phase 1b

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Oral topotecan + encequidar

Tinnitus, Ear illness/ disorder

Phase 1

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Oral irinotecan + encequidar

Solid tumor/s, Cancer

Phase 1

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Oral docetaxel + encequidar

Solid tumor/s, Cancer, Prostate cancer

Phase 1

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

ATNX

BPIQ_Logo_RGB-01.jpg

Company Profile

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. To achieve this, we have assembled an experienced leadership team and have established global operations across the pharmaceutical value chain.

Recent Posts

See what the community is saying - click to see full post.

ASCO 2021 Investor Hub - Presented Posters

ASCO 2021 Investor Hub - Updated

ASCO 2021 Investor Hub

ATNX - Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update

ATNX - Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

Will ATNX stock price pop if Oraxol gets approved?